GeneDx COO granted 10,430 restricted stock units

GeneDx Holdings Corp. reported that Chief Operating Officer Bryan Dechairo acquired 10,430 restricted stock units (RSUs) as an equity award.

Rhea-AI Filing Summary

GeneDx Holdings Corp. reported that Chief Operating Officer Bryan Dechairo acquired 10,430 restricted stock units (RSUs) as an equity award. Each RSU represents a contingent right to receive one share of Class A common stock for no cash consideration upon settlement.

The award vests over time, with 25% of the RSUs vesting each year on the anniversary of the grant date. The first tranche is scheduled to vest on April 1, 2027, provided Dechairo continues to serve the company on each vesting date. The RSUs have no expiration; they either vest or are cancelled before vesting.

Insider Trade Summary

Grant/Award: 10,430 shares

Grant/Award 1 txn

Insider Dechairo Bryan

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	10,430	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 10,430 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") reflected in this row represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, subject to continued service as described in footnote 2 below.
2. F2. 25% of the award shall vest annually on the anniversary of the grant date, with the first tranche vesting on April 1, 2027, subject to the Reporting Person's continued service to the Issuer on each vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GeneDx (WGS) report for Bryan Dechairo?

GeneDx reported that Chief Operating Officer Bryan Dechairo received 10,430 restricted stock units as an equity award. These RSUs convert into Class A common shares for no cash consideration when they vest, aligning part of his compensation with company performance over time.

How many restricted stock units did the GeneDx COO receive?

The GeneDx Chief Operating Officer was granted 10,430 restricted stock units. Each unit represents a right to receive one share of GeneDx Class A common stock upon settlement, creating a potential future ownership stake that depends on meeting the award’s vesting conditions.

How do the new RSUs for GeneDx COO Bryan Dechairo vest?

The RSUs vest in four equal annual installments, with 25% of the award vesting each year on the grant’s anniversary. The first tranche is scheduled to vest on April 1, 2027, assuming Bryan Dechairo continues serving GeneDx on each vesting date throughout the schedule.

What conditions apply to the GeneDx COO’s 10,430 RSUs?

The 10,430 RSUs are subject to continued service with GeneDx through each vesting date. They have no expiration date; instead, they will either vest according to the schedule if service conditions are met or be cancelled before vesting if those conditions are not satisfied.

What does each GeneDx RSU granted to the COO represent?

Each RSU granted to the COO represents a contingent right to receive one share of GeneDx’s Class A common stock upon settlement. No cash payment is required from the executive at settlement, making the award a form of stock-based compensation tied to ongoing service with the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 05:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dechairo Bryan

(Last) (First) (Middle)

C/O GENEDX HOLDINGS CORP.

333 LUDLOW ST., NORTH TOWER, 6TH FLOOR

(Street)

STAMFORD CT 06902

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GeneDx Holdings Corp. [ WGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/03/2026		A		10,430		(2)	(2)	Class A Common Stock	10,430	$0	10,430	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") reflected in this row represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, subject to continued service as described in footnote 2 below.

2. 25% of the award shall vest annually on the anniversary of the grant date, with the first tranche vesting on April 1, 2027, subject to the Reporting Person's continued service to the Issuer on each vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

	/s/ Bridget Brown, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.